Ftse Mib
34.650,95
0,91%
DAX
18.772,85
0,50%
S&P 500
5.214,90
0,02%
NASDAQ
16.333,18
-0,08%
Bitcoin
60.768,26
-3,62%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Taysha Gene Therapies Inc (TSHA) Taysha Gene Therapies Inc (TSHA) Notizie

Taysha Gene Therapies Inc

TSHA
2,365
-0,165 (-6,52%)
Ultimo aggiornamento: 18:58:20
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/5/202422:05GLOBETaysha Gene Therapies to Release First Quarter 2024..
03/5/202422:05GLOBETaysha Gene Therapies Announces Inducement Grant Under..
02/5/202414:00GLOBETaysha Gene Therapies Announces Regenerative Medicine..
05/4/202414:00GLOBETaysha Gene Therapies Announces Inducement Grant Under..
20/3/202418:30APSAnother Biotech Steals The Show Following Major Clinical..
19/3/202421:01GLOBETaysha Gene Therapies Reports Full Year 2023 Financial..
19/3/202412:27IHMARKETNEWSUS Index Futures Decline Ahead of Federal Reserve Meeting,..
14/3/202421:26GLOBETaysha Gene Therapies to Release Full-Year 2023 Financial..
01/3/202423:08GLOBETaysha Gene Therapies Announces Inducement Grant Under..
29/2/202414:00GLOBETaysha Gene Therapies Announces Updates to TSHA-102 Clinical..
15/2/202422:01GLOBETaysha Gene Therapies Provides Update on Deprioritized..
09/2/202422:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/2/202414:00GLOBETaysha Gene Therapies Announces Inducement Grant Under..
22/1/202414:00GLOBETaysha Gene Therapies Announces Poster Presentation on..
10/1/202414:06EDGAR2Form 8-K - Current report
10/1/202414:00GLOBETaysha Gene Therapies Announces First Pediatric Patient..
05/1/202414:00GLOBETaysha Gene Therapies Announces Inducement Grant Under..
20/12/202322:21EDGAR2Form 8-K - Current report
20/12/202322:20EDGAR2Form S-8 - Securities to be offered to employees in employee..
19/12/202313:30PRNUSTrinity Capital Inc. Provides $40 Million Term Loan to..
29/11/202314:00GLOBETaysha Gene Therapies Announces Expanded Eligibility in..
15/11/202322:29EDGAR2Form 8-K - Current report
14/11/202322:47EDGAR2Form 8-K - Current report
14/11/202322:08GLOBETaysha Gene Therapies Reports Third Quarter 2023 Financial..
07/11/202314:00GLOBETaysha Gene Therapies to Release Third Quarter 2023..
03/11/202321:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202321:40EDGAR2Form 3 - Initial statement of beneficial ownership of..
01/11/202321:02EDGAR2Form 8-K - Current report
24/10/202314:00GLOBETaysha Gene Therapies Presents New Preclinical In-vitro Data..
10/10/202314:00GLOBETaysha Gene Therapies Announces Two Poster Presentations on..
05/10/202313:00EDGAR2Form DEF 14A - Other definitive proxy statements
26/9/202314:08EDGAR2Form 8-K - Current report
26/9/202314:00GLOBETaysha Gene Therapies Announces Second Patient Dosed with..
21/9/202322:01EDGAR2Form PRE 14A - Other preliminary proxy statements
19/9/202322:52DJNTaysha Gene Therapies to End Development of TSHA-120 After..
19/9/202322:09EDGAR2Form 8-K - Current report
19/9/202322:01GLOBETaysha Gene Therapies Provides Update on TSHA-120 Program in..
11/9/202322:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
11/9/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
30/8/202322:02EDGAR2Form S-3 - Registration statement under Securities Act of..
29/8/202313:00EDGAR2Form 8-K - Current report
25/8/202322:22EDGAR2Form SC 13G - Statement of acquisition of beneficial..
24/8/202314:52DJNTaysha Gets FDA Fast-Track for Rett Syndrome Treatment
24/8/202314:09EDGAR2Form 8-K - Current report
24/8/202314:00GLOBETaysha Gene Therapies Announces Fast Track Designation..
14/8/202314:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202313:29EDGAR2Form 8-K - Current report
14/8/202313:02GLOBETaysha Gene Therapies Reports Initial Clinical Data from..
14/8/202313:00GLOBETaysha Gene Therapies Announces $150 Million Private..
04/8/202322:02EDGAR2Form 8-K - Current report
Apertura: 2,54 Min: 2,30 Max: 2,57
Chiusura: 2,53

La tua Cronologia

NASDAQ
TSHA
Taysha Gene Therapies
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network